简介：Dermatofibrosarcomaprotuberans(DFSP),themostcommondermalsarcoma,isalow-grade,slowgrowingfibroblasticmalignantneoplasmthatmostfrequentlyaffectsmiddleagedadultsandischaracterizedbyahighlocalrecurrencerateandalowpropensityformetastasis.WidesurgicalresectionorMohsmicrographicsurgery(MMS)arethepreferredapproachesforlocalizeddisease,whileradiationtherapyiswarrantedforinoperablediseaseorforcaseswithpositivemarginswherere-excisionisnotpossible.DFSPisgenerallyregardedasrefractorytoconventionalchemotherapy.Treatmentoptionsforsystemicdiseasewerelimiteduntilthediscoveryofauniquetranslocation,t(17;22)(q22;q13)(COL1A1;PDGFB)foundinamajorityofcases.Inrecentyears,imatinib,aPDGFβR,ABLandKITinhibitor,hasrevolutionizedsystemictherapyinDFSP.Inthisreview,wesummarizetheepidemiological,clinical,histologicalandgeneticcharacteristicsofDFSPandupdatethereadersonitscurrentmanagement.

简介：Inthecomingyearslifeexpectancyisexpectedtoincreaseandwiththisthepercentageofthepopulationaboveage65willgrow.Patientsabove65makeupmorethantwothirdsofthosecurrentlydiagnosedwithgastrointestinalmalignancies.Availableevidencebasedmedicinedoesnotfocusontheaveragepatient,abovetheage70,encounteredineverydaypractice.Mostguidelinesandclinicaltrialsarenotdesignedtotakeintoaccountthespecialconsiderationsneededwhentreatingtheelderlysuchasfunctionalstatus,comorbidities,polypharmacy,lifeexpectancy,andsocialsupport.Themajorityofavailabledataisbasedonretrospectivereviewsorsubsetanalysesoflargerstudieswheretheelderlyrepresentafractionofthestudiedpopulation.Thisreviewfocusesonthetoxicitiesandtolerabilityofcurrentstandardtherapiesfornoncolorectalgastrointestinalmalignancies,includinggastroesophageal,pancreatic,bileductandhepatocellularcancersintheelderly.Withcarefulpatientselectionandgeriatricassessmenttheelderlycansafelybenefitfromstandardtherapiesofferedtoyoungerpatients.

简介：Platinum-basedanticanceragentsarewidelyusedasfirst-linedrugsincancerchemotherapyforvarioussolidtumors.However,greatsideeffectsandoccurrenceofresistanceremainasthemajordrawbacksforalmostalltheplatinumdrugsdeveloped.Toconquertheseproblems,newstrategiesshouldbeadoptedforplatinumdrugbasedchemotherapy.Modernnanotechnologyhasbeenwidelyemployedinthedeliveryofvarioustherapeuticsanddiagnostic.Itprovidesthepossibilityoftargeteddeliveryofacertainanticancerdrugtothetumorsite,whichcouldminimizetoxicityandoptimizethedrugefficacy.Here,inthisreview,wefocusedontherecentprogressinpolymerbaseddrugdeliverysystemsforplatinum-basedcombinationtherapy.

简介：Inrecentyears,furtherunderstandingoftheinteractionbetweentheimmunesystemandtumorgrowthhasledtothedevelopmentofseveralimmunotherapies.Theseimmunotherapiesincludecancervaccinesandimmunecheckpointinhibitorsthathavebeentestedinvarioussolidtumors,includingthosetraditionallyconsiderednon-immunogenic,suchasnon-smallcelllung

简介：Risingworldwidecancerincidenceandresistancetocurrentanti-cancerdrugsnecessitatetheneedfornewpharmaceuticalcompoundsanddrugdeliverysystem.Malfunctionoftheimmunesystem,particularlyinthetumormicroenvironment,causestumorgrowthandenhancestumorprogression.Thus,cancerimmunotherapycanbeanappropriateapproachtoprovokethesystemicimmunesystemtocombattumorexpansion.Texosomes,whichareendogenousnanovesiclesreleasedbyalltumorcells,contributetocell-cellcommunicationandmodifythephenotypicfeaturesofrecipientcellsduetothetexosomes'abilitytotransportbiologicalcomponents.Forthisreason,texosome-baseddeliverysystemcanbeavaluablestrategyfortherapeuticpurposes.Toimprovethepharmaceuticalbehaviorofthissystemandtofacilitateitsuseinmedicalapplications,biotechnologyapproachesandmimetictechniqueshavebeenutilized.Inthisreview,wepresentthedevelopmenthistoryoftexosome-baseddeliverysystemsanddiscusstheadvantagesanddisadvantagesofeachsystem.

简介：Immunecheckpointinhibitorsareincreasinglydrawingmuchattentioninthetherapeuticdevelopmentforcancertreatment.However,manycancerpatientsdonotrespondtotreatmentswithimmunecheckpointinhibitors,partlybecauseofthelackoftumor-infiltratingeffectorTcells.CancervaccinesmayprimepatientsfortreatmentswithimmunecheckpointinhibitorsbyinducingeffectorT-cellinfiltrationintothetumorsandimmunecheckpointsignals.Thecombinationofcancervaccineandanimmunecheckpointinhibitormayfunctionsynergisticallytoinducemoreeffectiveantitumorimmuneresponses,andclinicaltrialstotestthecombinationarecurrentlyongoing.

简介：Objective:Humaninducedpluripotentstem(iPS)cellsexhibitgreatpotentialforgeneratingfunctionalhumancellsformedicaltherapies.Inthispaper,wereportforuseofhumaniPScellslabeledwithfluorescentmagneticnanoparticles(FMNPs)fortargetedimagingandsynergistictherapyofgastriccancercellsinvivo.Methods:HumaniPScellswerepreparedandculturedfor72h.Theculturemediumwascollected,andthenwascoincubatedwithMGC803cells.CellviabilitywasanalyzedbytheMTTmethod.FMNP-labeledhumaniPScellswerepreparedandinjectedintogastriccancer-bearingnudemice.Themousemodelwasobservedusingasmall-animalimagingsystem.Thenudemicewereirradiatedunderanexternalalternatingmagneticfieldandevaluatedusinganinfraredthermalmappinginstrument.Tumorsizesweremeasuredweekly.Results:iPScellsandthecollectedculturemediuminhibitedthegrowthofMGC803cells.FMNP-labeledhumaniPScellstargetedandimagedgastriccancercellsinvivo,aswellasinhibitedcancergrowthinvivothroughtheexternalmagneticfield.Conclusion:FMNP-labeledhumaniPScellsexhibitconsiderablepotentialinapplicationssuchastargeteddual-modeimagingandsynergistictherapyforearlygastriccancer.

简介：Palliativeradiotherapy(pRT)isprimarilyemployedforpalliationofbonepaininpatientswithcastrate-resistantprostatecancer(CRPC).However,evidencethatpRTinfluencesprostate-specificantigenresponseinpatientswithCRPConsystemictherapyislacking.WedescribethreecasesofCRPCprogressingaftertreatmentwithdocetaxel(n=2)andabiraterone(n=1),whorespondedunusuallyafterpRTforbonepainwiththedevelopmentofasignificantbiochemicalresponseandrestorationofresponsetosystemictherapy.ThepossibilityofpRTinfluencingmetastaticdiseaseinCRPChasnotbeenpreviouslyreported,andraisesthepossibilityofradiation-inducedmodulationofanti-tumorimmuneresponsemechanismsthatmayplayaroleintherestorationofresponsetosystemictreatment.